All In Biotech

Investigational drug · Phase 3

CHF10196

Also called: florensocatib

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Bronchiectasis.

Phase 3

Last checked: Nov 19, 2026Latest source record: Jun 24, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

1

1 still active

All registered trials

3

Any phase or sponsor naming "CHF10196"

First trial start

2026

Nov 2026

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "CHF10196", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Bronchiectasis

Approved drugs for the same conditions: Respiratory

Largest trials

Live from ClinicalTrials.gov: studies naming "CHF10196" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 3 on PubMed

Also in development for Bronchiectasis

  • ItepekimabREGN3500, SAR440340Phase 39 trials

    Sanofi · Chronic Obstructive Pulmonary Disease, Chronic Rhinosinusitis With Nasal Polyps, Bronchiectasis

  • VerducatibBI 1291583Phase 34 trials

    Boehringer Ingelheim · Bronchiectasis, Chronic Obstructive Pulmonary Disease

  • HSK31858Phase 33 trials

    Haisco Pharmaceutical Group Co., Ltd. · Non-cystic Fibrosis Bronchiectasis, Asthma Bronchiale, Bronchiectasis

  • GSK3862995BPhase 22 trials

    GSK · Bronchiectasis, Pulmonary Disease, Chronic Obstructive

  • CHF6333Phase 21 trial

    Chiesi Farmaceutici S.p.A. · Bronchiectasis

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.